Clinical Trials Directory
In this study, all participants will receive a study medicine called xaluritamig through a tube placed in a vein. Each treatment takes about one hour. At the start, lower doses are given every two weeks. Later, treatments are given every four weeks. Before starting, you will have tests such as blood work, scans, and a physical exam to make sure you can join the study. During the study, you will have regular clinic visits for treatments, checkups, blood tests, and scans like CT or MRI to watch your health and your cancer. Early in treatment, you may need to stay at the clinic or hospital for a short time after the medicine is given so doctors can monitor you. You will also need a caregiver to help you for a short time after treatment. You can keep receiving the medicine as long as it is helping you, and doctors will continue to check on you for up to about two years.
We are doing this study to compare how safe and effective different drug combinations are for treating metastatic cancer.
We are doing this study to learn more about how androgens, a type of sex hormone, might affect women who have nonalcoholic fatty liver disease (NAFLD). We want to see if they play a role in how the disease effects women over time, and we also want to see what role these hormones might play in the relationship between NAFLD and polycystic ovary syndrome.
We are doing this study to find the most effective, safe dose of a combination of the drugs fianlimab and ceminplimab. We want to know if this combination is an option for people with melanoma. We will compare how well this drug combination works to the usual treatment of relatlimab and nivolumab, which has the brand name Opdualag®.
If you join this study, you will be randomly placed into one of two groups. One group will get the study medicine called efgartigimod, and the other group will get a placebo, which is a fake medicine. Both are given through a tube in your vein, called an IV. You will get the medicine or placebo for the first 4 weeks. After that, depending on your platelet count, you will keep getting it every week or every other week for 20 more weeks. After 24 weeks, you may be able to join the next part of the study, where everyone gets the real medicine for up to 52 weeks. If the medicine does not work well enough after 12 weeks, you might be able to switch to the real medicine earlier.